Top

Published in:

Open Access 01-01-2017 | Consensus Paper

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Authors: Kristian W. Pajtler, Stephen C. Mack, Vijay Ramaswamy, Christian A. Smith, Hendrik Witt, Amy Smith, Jordan R. Hansford, Katja von Hoff, Karen D. Wright, Eugene Hwang, Didier Frappaz, Yonehiro Kanemura, Maura Massimino, Cécile Faure-Conter, Piergiorgio Modena, Uri Tabori, Katherine E. Warren, Eric C. Holland, Koichi Ichimura, Felice Giangaspero, David Castel, Andreas von Deimling, Marcel Kool, Peter B. Dirks, Richard G. Grundy, Nicholas K. Foreman, Amar Gajjar, Andrey Korshunov, Jonathan Finlay, Richard J. Gilbertson, David W. Ellison, Kenneth D. Aldape, Thomas E. Merchant, Eric Bouffet, Stefan M. Pfister, Michael D. Taylor

Published in: Acta Neuropathologica | Issue 1/2017

Abstract

Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM et al (2011) An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384–399. doi:10.1016/j.ccr.2011.08.013 CrossRefPubMedPubMedCentral

Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S et al (2014) Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathol 128:863–877. doi:10.1007/s00401-014-1327-6 CrossRefPubMedPubMedCentral

Bouffet E, Foreman N (1999) Chemotherapy for intracranial ependymomas. Child’s Nerv Syst ChNS 15:563–570CrossRef

Bouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, Tsangaris E, Huang A, Kulkarni A, Mabbot DJ et al (2012) Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 83:1541–1548. doi:10.1016/j.ijrobp.2011.10.039 CrossRefPubMed

Bouffet E, Perilongo G, Canete A, Massimino M (1998) Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30:319–329 (discussion 329–331) CrossRefPubMed

Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT, Auguste KI (2013) A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediatr 11:673–681. doi:10.3171/2013.2.peds12345 CrossRefPubMed

Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, Perry R, Walker D, Gilbertson R, Ellison DW (2002) Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 86:929–939. doi:10.1038/sj.bjc.6600180 CrossRefPubMedPubMedCentral

Dyer S, Prebble E, Davison V, Davies P, Ramani P, Ellison D, Grundy R (2002) Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 161:2133–2141. doi:10.1016/s0002-9440(10)64491-4 CrossRefPubMedPubMedCentral

Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, Frappaz D, Massimino M, Grill J, Boyett JM et al (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7. doi:10.1186/1477-5751-10-7 CrossRefPubMedPubMedCentral

10.

Garvin JH Jr, Selch MT, Holmes E, Berger MS, Finlay JL, Flannery A, Goldwein JW, Packer RJ, Rorke-Adams LB, Shiminski-Maher T et al (2012) Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: a report from the Children’s Oncology Group. Pediatr Blood Cancer 59:1183–1189. doi:10.1002/pbc.24274 CrossRefPubMed

11.

Ghia AJ, Mahajan A, Allen PK, Armstrong TS, Lang FF Jr, Gilbert MR, Brown PD (2013) Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. J Neurooncol 115:513–520. doi:10.1007/s11060-013-1254-8 CrossRefPubMed

12.

Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA, Boop FA, Gajjar A, Merchant TE, Ellison DW (2012) Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 124:247–257. doi:10.1007/s00401-012-0981-9 CrossRefPubMedPubMedCentral

13.

Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O et al (2016) Chemotherapy for intracranial ependymoma in adults. BMC Cancer 16:287. doi:10.1186/s12885-016-2323-0 CrossRefPubMedPubMedCentral

14.

Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC et al (2001) Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19:1288–1296PubMed

15.

Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC et al (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8:696–705. doi:10.1016/s1470-2045(07)70208-5 CrossRefPubMed

16.

Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary SE, White E, Eden C et al (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466:632–636. doi:10.1038/nature09173 CrossRefPubMedPubMedCentral

17.

Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J et al (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18:2001–2011. doi:10.1158/1078-0432.ccr-11-2489 CrossRefPubMed

18.

Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A et al (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182–3190. doi:10.1200/jco.2009.27.3359 CrossRefPubMed

19.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

20.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. doi:10.1007/s00401-016-1545-1 CrossRefPubMed

21.

Macdonald SM, Sethi R, Lavally B, Yeap BY, Marcus KJ, Caruso P, Pulsifer M, Huang M, Ebb D, Tarbell NJ et al (2013) Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro-oncology 15:1552–1559. doi:10.1093/neuonc/not121 CrossRefPubMedPubMedCentral

22.

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. doi:10.1038/nature13108 PubMedCentral

23.

Mack SC, Witt H, Wang X, Milde T, Yao Y, Bertrand KC, Korshunov A, Pfister SM, Taylor MD (2013) Emerging insights into the ependymoma epigenome. Brain Pathol (Zurich, Switzerland) 23:206–209. doi:10.1111/bpa.12020

24.

Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070–2079. doi:10.1158/1078-0432.CCR-05-2363 CrossRefPubMed

25.

Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10:258–266CrossRefPubMedPubMedCentral

26.

Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I et al (2011) A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 122:637–650. doi:10.1007/s00401-011-0866-3 CrossRefPubMedPubMedCentral

27.

Mohankumar KM, Currle DS, White E, Boulos N, Dapper J, Eden C, Nimmervoll B, Thiruvenkatam R, Connelly M, Kranenburg TA (2015) An in vivo screen identifies ependymoma oncogenes and tumor-suppressor gene. Nat Genet 47:878–887. doi:10.1038/ng.3323 CrossRefPubMedPubMedCentral

28.

Nuno M, Yu JJ, Varshneya K, Alexander J, Mukherjee D, Black KL, Patil CG (2016) Treatment and survival of supratentorial and posterior fossa ependymomas in adults. J Clin Neurosci 28:24–30. doi:10.1016/j.jocn.2015.11.014 CrossRefPubMed

29.

Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743. doi:10.1016/j.ccell.2015.04.002 CrossRefPubMedPubMedCentral

30.

Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R et al (2014) C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. doi:10.1038/nature13109

31.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K et al (2016) Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol. doi:10.1200/jco.2015.65.7825

32.

Rand V, Prebble E, Ridley L, Howard M, Wei W, Brundler MA, Fee BE, Riggins GJ, Coyle B, Grundy RG (2008) Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. Br J Cancer 99:1136–1143. doi:10.1038/sj.bjc.6604651 CrossRefPubMedPubMedCentral

33.

Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J et al (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323–335. doi:10.1016/j.ccr.2005.09.001 CrossRefPubMed

34.

Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Modern Pathol 21:165–177. doi:10.1038/modpathol.3800999

35.

Venkatramani R, Dhall G, Patel M, Grimm J, Hawkins C, McComb G, Krieger M, Wong K, O’Neil S, Finlay JL (2012) Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer 58:380–383. doi:10.1002/pbc.23086 CrossRefPubMed

36.

Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M et al (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123:727–738. doi:10.1007/s00401-012-0941-4 CrossRefPubMedPubMedCentral

37.

Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143–157. doi:10.1016/j.ccr.2011.07.007 CrossRefPubMedPubMedCentral

38.

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A (2015) Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-oncology 17:1620–1627. doi:10.1093/neuonc/nov181 CrossRefPubMedPubMedCentral

39.

Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM et al (2010) A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol 12:580–594. doi:10.1093/neuonc/nop056 CrossRefPubMedPubMedCentral

40.

Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC, Dunkel I, Diez B, Sposto R, Ji L et al (2007) Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49:34–40. doi:10.1002/pbc.20935 CrossRefPubMed

Title: The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
Authors: Kristian W. Pajtler
Stephen C. Mack
Vijay Ramaswamy
Christian A. Smith
Hendrik Witt
Amy Smith
Jordan R. Hansford
Katja von Hoff
Karen D. Wright
Eugene Hwang
Didier Frappaz
Yonehiro Kanemura
Maura Massimino
Cécile Faure-Conter
Piergiorgio Modena
Uri Tabori
Katherine E. Warren
Eric C. Holland
Koichi Ichimura
Felice Giangaspero
David Castel
Andreas von Deimling
Marcel Kool
Peter B. Dirks
Richard G. Grundy
Nicholas K. Foreman
Amar Gajjar
Andrey Korshunov
Jonathan Finlay
Richard J. Gilbertson
David W. Ellison
Kenneth D. Aldape
Thomas E. Merchant
Eric Bouffet
Stefan M. Pfister
Michael D. Taylor
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 1/2017
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-016-1643-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy

Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis

An updated histological classification system for multiple sclerosis lesions

Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis

Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging